FDA & PDA Work to Align Manufacturing Goals with Patient Needs

March 23, 2016

On Tuesday March, 22nd FDA announced a public conference, entitled “Aligning Manufacturing Goals with Patient Needs through Successful Innovation and Compliance,” to be held in co-sponsorship with the Parenteral Drug Association (PDA).

FDA and PDA hold an annual Joint Regulatory Conference, which provides a unique opportunity for participants to engage with FDA representatives and industry experts in face-to-face dialogue. Each year, the conference focuses on the “current issues affecting the industry,” and explores different strategies to expedite the development and continuous improvement of safe and effective medical products.

The conference helps ensure the quality of FDA-regulated products by helping to achieve the objectives set forth in section 406 of the FDA Modernization Act of 1997. These objectives include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public.

During the conference participants will have the chance “to discuss the foundations, emerging technologies, and innovations in regulatory science, as well as the current quality and compliance areas of concerns.” Participants will hear from a number of speakers from the industry as well as representatives from the Agency who will delve into the “requirements and best practices to consider while implementing robust quality systems in order to deliver the best quality product.” The topics that will be discussed throughout a series of sessions and meetings include, but are not limited to:

The 2016 FDA-PDA Joint Regulatory Conference will be held from September 12 to 14, 2016 at the Renaissance Washington DC Downtown Hotel. Registration is required, and those interested in attending the conference are encouraged to register as soon as possible, as space is limited and on a first come first served basis. On-site registration will be offered as space allows and will begin at 1pm on September 11, 2016, and at 7am from September 12 through 14, 2016.

To learn more or to register online, visit the PDA’s website.

Our regulatory group specializes in all things pertaining to an FDA submission and can help get your product approved by the Agency in the most time and cost effective manner.  To learn more about our servicescontact us today.

TAGS:

March 7, 2017

FDA to Hold Public Meeting to Discuss Patient-Focused Drug Development for Autism

On Monday, March 6th, the FDA announced plans to hold a public meeting regarding the development of patient-focused drugs for autism. In the notice published in the Federal Register, the FDA notes...

September 13, 2018

FDA Releases Draft Guidance on Benefit-Risk Determinations for Devices

On Thursday, September 6th, the FDA released a new draft guidance regarding benefit-risk determinations in medical device premarket approval applications (PMAs), De Novo requests, and humanitarian...

July 19, 2017

FDA Issues Draft Standardization of Pharmaceutical Quality/Chemistry Manufacturing and Control Data Elements and Terminologies, Requests Comments

On Tuesday, July 11th, FDA released its draft standardized Pharmaceutical Quality/Chemistry Manufacturing and Control (PQ/CMC) data elements and terminologies for the electronic submission of this...